ClinicalTrials.gg
CompletedNCT05283681Updated Mar 17, 2022

A Study to Evaluate the Bioavailability of Risankizumab in Pre-filled Syringe or Auto-injector in Healthy Adult Participants

A Phase 1 interventional study of Risankizumab and Risankizumab in Healthy Volunteers, sponsored by AbbVie. Completed at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-17.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Primary completion was Nov 2019, 7 years ago, and no results have been posted to the registry.
  • Registered 2 years 11 months after the study started (first participant enrolled Apr 2019, registered Mar 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
226
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The objective of this study is to evaluate the bioavailability of risankizumab new formulation in prefilled syringe (PFS) relative to the 90 mg/mL formulation in PFS in healthy volunteers. The study will also evaluate the bioavailability of risankizumab new formulation in auto-injector (AI) relative to PFS in healthy volunteers.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female healthy volunteers between 18 and 55 years of age.
  • Body weight less than 110.00 kg inclusive at Screening.

Exclusion criteria

Exclusion Criteria:

  • Previous exposure to any anti-IL-12/23 or anti-IL-23 treatment.
  • Intention to perform strenuous exercise to which the subject is unaccustomed within one week prior to administration of study drug or during the study.
05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
226 participants (actual)

Study arms

  • Experimental
    Risankizumab Dose A

    Participants will receive 1 Subcutaneous (SC) injection of risankizumab Dose A administered via Prefilled Syringe (PFS) at Day 1 and followed for 140 days

    Drug: Risankizumab

  • Experimental
    Risankizumab Dose B

    Participants will receive SC injections of risankizumab Dose B administered via PFS at Day 1 and followed for 140 days

    Drug: Risankizumab

  • Experimental
    Risankizumab Dose C

    Participants will receive 1 SC injection of risankizumab Dose C administered via Auto-Injector (AI) at Day 1 and followed for 140 days.

    Drug: Risankizumab

Interventions

  • Subcutaneous Injection via Prefilled Syringe (PFS)

    Also known as: ABBV-066, SKYRIZI

  • Subcutaneous Injection via Auto-Injector (AI)

    Also known as: ABBV-066, SKYRIZI

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product which does not necessarily have a causal relationship with the treatment. The investigator assesses the relationship of each event to the use of study drug.

    Time frame: Up to 140 Days

  2. Maximum observed serum concentration (Cmax)

    Maximum observed serum concentration

    Time frame: Up to 113 Days

  3. Time to Cmax (Tmax)

    Time to Cmax

    Time frame: Up to 113 Days

  4. Terminal phase elimination rate constant (β)

    Terminal phase elimination rate constant

    Time frame: Up to 113 Days

  5. Terminal phase elimination half-life (t1/2)

    Terminal phase elimination half-life

    Time frame: Up to 113 Days

  6. Area under the concentration-time curve (AUC) from time 0 to time of the last measurable concentration (AUCt)

    AUC from 0 to time of last measurable concentration

    Time frame: Up to 113 Days

  7. AUC from time 0 to infinity (AUCinf)

    AUC from time 0 to infinity

    Time frame: Up to 113 Days

  8. Number of Anti-drug antibody (ADA) Titers

    Incidence of anti-drug antibodies

    Time frame: Up to 113 Days

07

Study locations

2 sites
  • Acpru /Id# 210844
    Grayslake, Illinois 60030, United States
  • PPD Clinical Research Unit - Austin /ID# 211456
    Austin, Texas 78744, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2019 to primary completion in Nov 2019, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 9, 2022
First posted
Mar 17, 2022
StartActual
Apr 2, 2019
Primary completionActual
Nov 11, 2019
CompletionActual
Nov 11, 2019
Last update
Mar 17, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 17, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05283681
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Mar 17, 2022
Start date
Apr 2, 2019
Primary completion
Nov 11, 2019
Completion
Nov 11, 2019
Last update
Mar 17, 2022

Study contacts

ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Risankizumab

Start the discussion